Researchers evaluated the impact of integrating whole-genome sequencing data with clinical outcomes across 13,880 tumors from 33 cancer types, assessing precision care potentials within the UK NHS through the 100,000 Genomes Cancer Programme.
FDA approves Syndax’s Revuforj to treat leukaemia
The approval marks the therapy as the first and only menin inhibitor for treating patients one year and older with relapsed or refractory acute leukaemia